leisure time -WSS

leisure time

author：knowledge 2025-10-01 00:57:51 - browse：8

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Questions and answers about ramping up H5N1 bird flu vaccine

entertainment

knowledge

WSS

Russian and Belarusian players banned from a women's tennis tournament in Prague

ASCO eve: Let’s set the table for this year's meeting

Bird flu surveillance in wastewater gets boost from consortium

Poland's lawmakers approve a divisive law on Russian influence

5 wounded, 2 critically, in Michigan shopping center shooting

Reports of telehealth's death have been greatly exaggerated

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

23andMe had bad news about my health. I wish a person had delivered it

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

What does generative AI mean for health care? We asked experts

Europe is fastest

Affirmative action in medical school literally saved lives

Digital health: a case of mistaken identity

Psychedelics group wrestles with new pharma identity

Citing H5N1 threat, CDC urges peak flu monitoring this summer

How one medical school became remarkably diverse

Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources

hotspot

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

Europe is fastest

HCA says smaller share of spending going to labor

Teacher posts viral 'school supply rant' with advice for parents

Campaign finance charge dropped from case against Sam Bankman

Addressing health care workers' trauma can help fight burnout

entertainment

knowledge

hotspot

hotspot